Welcome to the: Orthopaedic Opinion Online Website

The website for the answer to all your Orthopaedic Questions

- Orthopaedic Opinion Online is a website designed to provide information to
 patients who have orthopaedic and musculoskeletal problems and are undergoing
 treatment.
- Patient information is provided in the form of downloadable information sheets.
- Orthopaedic advice and second opinions can be provided by our expert internationally renowned Consultant Orthopaedic Surgeons.
- Online review of patients' X rays or MRI scans can also be provided and any proposed treatment plans reviewed.
- **Book a clinical consultation** with one of our internationally renowned consultant orthopaedic surgeons in Bristol or London.
- Orthopaedic reports can be provided for Injury or Accident Claims and Medical Negligence claims.

This Patient Information Sheet is provided by Orthopaedic Opinion Online

Platelet Rich Plasma Injection

"The new injection for sports injuries and tendonitis"

Author:

DAVID P JOHNSON

MB ChB FRCS FRCS(Orth). MD Consultant Orthopaedic Surgeon www.Bristol-Knee-Clinic.co.uk

About PRP Therapy

Platelet Rich Plasma Injection (PRP) therapy offers a promising solution to accelerate healing of tendon injuries and osteoarthritis naturally without subjecting the patient to significant risk. PRP is an emerging treatment in a new health sector known as "Orthobiologics." The philosophy is to merge cutting edge bio-technology with the body's natural ability to heal itself.

Blood is made of RBC (Red Blood Cells), WBC (White Blood Cells), Plasma, and Platelets. When in their resting state, platelets look like sea sponges and when activated form branches. Platelets were initially known to be responsible for blood clotting. In the last 20 years we have learned that when activated in the body, platelets release healing proteins called growth factors. There are many growth factors with varying responsibilities, however cumulatively they accelerate tissue and wound healing. Therefore after increasing the concentration of these platelets into a small injection, we are able to deliver a powerful cocktail of growth factors that can dramatically enhance tissue recovery.

Three commonly utilised techniques for delivery of the PRP are known as platelet-rich plasma, autologous blood injections and autologous conditioned serum. Each of these techniques has been studied clinically in humans to a limited degree in respect of the healing of tendon and ligamentous injuries. The results are promising in terms of earlier return to play following muscle and particularly tendon injury.

The following growth factors can be found in the environment of a blood clot:

- transforming growth factor beta (TGF-b)
- platelet-derived growth factor (PDGF)
- insulin-like growth factor (IGF)

- vascular endothelial growth factors (VEGF)
- epidermal growth factor (EGF)
- fibroblast growth factor-2 (FGF-2)

Clinical use of platelet-rich plasma in orthopaedics

The increasing use of platelet-rich plasma (PRP) in orthopaedics presents significant opportunities—as well as significant questions—about appropriate clinical applications for this developing therapy. PRP was initially developed in the 1970s; recent technologic advances have enabled the administration of PRP to move from the hospital setting into outpatient and ambulatory surgical centers...even into physicians' offices. PRF has been referred to as a second-generation platelet concentrate. PRF has been shown to have various advantages over traditionally prepared PRP. Its chief advantages include ease of preparation, the lack of biochemical handling of blood, and a prolonged release of local growth hormones.

Although PRP / PRF therapy seems quite promising in several areas, it is not appropriate in all cases. A clear understanding of the repair response, the development of PRP / PRF therapy, and the variables that may affect the effectiveness of PRP / PRF therapy is necessary to make informed clinical judgments on its use.

Clinical Preparation of PRP injection

First, a small amount of blood is drawn from the patient's arm. The blood is then placed in a centrifuge that spins the blood for approximately 15 minutes. This step removes the unwanted components of blood that are not primarily responsible for healing including: plasma, WBC's and RBC's. What remains is an increased concentration of up to ten times the concentration of platelets, which are rich in the desired growth factors to potentiate enhanced healing. During this time, the patient receives a local anesthetic injection.



The blood is injected into a separation chamber for centrification and separation of the platelet rich plasma.



A centrifuge is used to isolate the platelets, which are rich in growth factors.

PRP Injection

A clinical diagnosis must first be made with the assistance of invetsigations such as haematological tests, MRI scans, X-rays or ultrasound. Only if the injury or problem area is sutiable for PRP / PRF therapy is treatment undertaken. Conditions suitable include:

- 1 Acute or chronic soft tissue injuries
- 2 Acte and chronic ligamentous injuries
- 3 Tendonitis
- 4 Tennis elbow
- 5 De Quervains syndroms
- 6 Achilles tendonitis
- 7 Plantar fasciitis
- 8 Patellar tendonitis

The area of injury is properly identified and marked. The injection is performed by a simple percutaneous injection. The patient rests afterwards for 5-10 minutes and is discharged home with post procedure instructions. Increased pain may result for approximately 7 days following the injection which is not uncommon. This represents part of the healing process.

Follow Up

Follow up is usually in 4 weeks, when clinical examination or clinical ultrasound will be performed to reassess the area of injury. At that time if symptoms persist then a second injection is required. For most cases between 1-3 injections is required at 4 week intervals. However for osteoarthritis injections a three-injection series is required at 4 week intervals. Patients are encouraged to participate in physical therapy following the injection which enhances recovery.

References:

- Rai B, Oest ME, Dupont KM, Ho KH, Teoh SH, Guldberg RE: Combination of plateletrich plasma with polycaprolactone-tricalcium phosphate scaffolds for segmental bone defect repair. J Biomed Mater Res A 2007;81:888-899.
- 2. Sipe JB, Zhang J, Waits C, Skikne B, Garimella R, Anderson HC: Localization of bone morphogenetic proteins (BMPs)-2, -4, and -6 within megakaryocytes and platelets. *Bone* 2004;35:1316-1322.
- Kark LR, Karp JM, Davies JE: Platelet releasate increases the proliferation and migration of bone marrow-derived cells cultured under osteogenic conditions. Clin Oral Implants Res 2006;17:321-327.
- 4. Gruber R, Kandler B, Fischer MB, Watzek G: Osteogenic differentiation induced by bone morphogenetic proteins can be suppressed by platelet-released supernatant in vitro. *Clin Oral Implants Res* 2006;17:188-193.

- Ranly DM, McMillan J, Krause WF, Lohmann CH, Boyan BD, Schwartz Z: Platelet-rich plasma: A review of its components and use in bone repair, in Akay M (ed): Encyclopedia of Biomedical Engineering, vol 5. Hoboken, NJ: John Wiley & Sons, Inc., 2006, pp 2804-2815.
- Ranly DM, Lohmann CH, Andreacchio D, Boyan BD, Schwartz Z. Platelet-rich plasma inhibits demineralized bone matrix-induced bone formation in nude mice. *J Bone Joint Surg Am* 2007;89:139-147.
- Schwartz Z, Somers A, Mellonig JT, et al: Ability of commercial demineralized bone allograft to induce bone formation is donor age-dependent but not genderdependent (abstract). Trans Orthopaed Res Soc 1997;22:230.
- 8. Weibrich G, Kleis WK, Hitzler WE, Hafner G. Comparison of the platelet concentrate collection system with the plasma-rich-in-growth-factors kit to produce platelet-rich plasma: A technical report. *Int J Oral Maxillofac Implants* 2005;20:118-123.
- 9. Thibault L, Beausejour A, de Grandmont MJ, Lemieux R, Leblanc JF: Characterization of blood components prepared from whole-blood donations after a 24-hour hold with the platelet-rich plasma method. *Transfusion* 2006;46:1292-1299.
- Li H, Zou X, Xue Q, Egund N, Lind M, Bunger C: Anterior lumbar interbody fusion with carbon fiber cage loaded with bioceramics and platelet-rich plasma: An experimental study on pigs. Eur Spine J 2004;13:354-358.
- Weiner BK, Walker M: Efficacy of autologous growth factors in lumbar intertransverse fusions. Spine 2003;28:1968-1970.
- 12. Muschler GF, Nitto H, Matsukura Y, et al: Spine fusion using cell matrix composites enriched in bone marrow-derived cells. *Clin Orthop Relat Res* 2003;(407):102-118.
- 13. Muschler GF, Matsukura Y, Nitto H, et al: Selective retention of bone marrow-derived cells to enhance spinal fusion. *Clin Orthop Relat Res* 2005;(432):242-251.
- Brodke D, Pedrozo HA, Kapur TA, et al: Bone grafts prepared with selective cell retention technology heal canine segmental defects as effectively as autograft. J Orthop Res 2006;24:857-866.
- Murray MM, Spindler KP, Ballard P, Welch TP, Zurakowski D, Nanney LB: Enhanced histologic repair in a central wound in the anterior cruciate ligament with a collagenplatelet-rich plasma scaffold. J Orthop Res 2007;25:1007-1017.

Disclaimer: The views expressed in this article are not necessarily those of Orthopaedic Opinion Online or the author. The information is provided for general background reading only and should not be relied upon for treatment. Advice should always be taken from a registered medical practitioner for individual circumstances and for treatment of any patient in any circumstances. No liability is accepted by Orthopaedic Opinion Online, or the author in respect to the information provided in respect of the content or omission or for any reason or as a result of treatment in individual circumstances. This information is not for use in the USA.